The Hidradenitis Suppurativa market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Hidradenitis Suppurativa: An Overview
Hidradenitis Suppurativa (HS) is a complex dermatological disease characterized by recurrent painful nodules and suppuration in areas such as the axilla and groin. It is also known as Acne inversa and there is no biological or pathological test to facilitate diagnosis, it can be defined by its clinical features and its chronicity.
Systemic therapies mainly antibiotics along with retinoids are the mainstay of treatment. Topical therapies are mainly used in the case of mild to moderate disease conditions. Adalimumab (Humira) is the only approved drug available for the treatment of moderate to severe HS.
Biosimilars of Humira are expected to enter the US market by 2023 and are expected to decline the overall dollar value. The market value of Humira in Europe is already started declining from 2018 and declining in sales value is expected to be much faster in future years due to multiple launches of biosimilars. Patient share of overall adalimumab is also expected to decline due to the expected entry of more efficacious emerging products, however, biosimilars with lower prices are expected to control the damage.
Hidradenitis Suppurativa Market Key Facts
-
The diagnosed prevalent population of Hidradenitis Suppurativa in seven major markets has been estimated to be around 1,230,513 for 2020, which is expected to rise by 2030 according to DelveInsight estimates. It is important to mention that most Hidradenitis Suppurativa cases remain underdiagnosed for years.
-
As per DelveInsight’s analysis, a higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM.
-
According to DelveInsight’s analysis, among the diagnosed prevalent pool of Hidradenitis Suppurativa in the 7MM, the highest proportion of HS was observed in the 30–39 years age group among all the countries. More than 90% of cases of HS are reported in patients age 18 years and above.
-
Among the European 5 countries, Germany had the highest prevalent population followed by France and the United Kingdom.
-
In 2020, the diagnosed prevalent cases of Hidradenitis Suppurativa in the United States were estimated to be 567,698 and expected to increase by 2030 mainly due to an increase in population.
Hidradenitis Suppurativa Market
Hidradenitis Suppurativa Market Size is anticipated to increase during the study period owing to the increasing prevalent pool, better diagnosis rate, and expected entries of emerging therapies in the 7MM.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Hidradenitis Suppurativa market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Hidradenitis Suppurativa market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Hidradenitis Suppurativa Epidemiology
The epidemiology section covers insights about the historical and current Hidradenitis Suppurativa patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Hidradenitis Suppurativa Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hidradenitis Suppurativa market or expected to get launched in the market during the study period. The analysis covers Hidradenitis Suppurativa market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Hidradenitis Suppurativa Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market
Hidradenitis Suppurativa Therapeutics Analysis
The available therapeutics treatment options in Hidradenitis Suppurativa (HS) Landscape aim to reduce complications arising from blockage of hair follicles and secondary infection and sometimes inflammation of certain sweat glands (apocrine glands).
The dynamics of the Hidradenitis Suppurativa therapeutic market is anticipated to change in the coming years owing to the improvement in healthcare spending across the world. Major Pharmaceutical giants are thoroughly working toward the development of new treatment therapies for this indication, in order to provide better relief for the symptoms and hence improve the Quality of life (QoL) of patients with HS.
Hidradenitis Suppurativa (HS) Companies:
-
Novartis
-
InflaRx
-
ChemoCentryx
-
UCB Biopharma
-
Incyte Corporation
-
Abbvie
-
Janssen Pharmaceutical
-
Xbiotech
-
CSL Behring
And many others
Hidradenitis Suppurativa (HS) Therapies covered in the report include:
-
IFX-1
-
Cosentyx/Secukinumab
-
Avacopan
-
Bimekizumab
-
Bermekimab (MABp1)
-
INCB054707
And many more.
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market
Table of Content
1. Key Insights
2. Executive Summary
3. Hidradenitis Suppurativa Competitive Intelligence Analysis
4. Hidradenitis Suppurativa Market Overview at a Glance
5. Hidradenitis Suppurativa Disease Background and Overview
6. Hidradenitis Suppurativa Patient Journey
7. Hidradenitis Suppurativa Epidemiology and Patient Population
8. Hidradenitis Suppurativa Treatment Algorithm, Current Treatment, and Medical Practices
9. Hidradenitis Suppurativa Unmet Needs
10. Key Endpoints of Hidradenitis Suppurativa Treatment
11. Hidradenitis Suppurativa Marketed Products
12. Hidradenitis Suppurativa Emerging Therapies
13. Hidradenitis Suppurativa Seven Major Market Analysis
14. Attribute Analysis
15. Hidradenitis Suppurativa Market Outlook (7 major markets)
16. Hidradenitis Suppurativa Access and Reimbursement Overview
17. KOL Views on the Hidradenitis Suppurativa Market.
18. Hidradenitis Suppurativa Market Drivers
19. Hidradenitis Suppurativa Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market
Other Latest Healthcare Reports By DelveInsight
Malignant Pleural Mesothelioma (MPM) Market
Malignant Pleural Mesothelioma (MPM) Market is anticipated to grow in the coming years owing to the improvement in healthcare spending across the world, rising prevalence, and the active participation of the key companies in the therapeutics domain such as Sellas, Polaris Pharma, Targovax, among others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/